A lead BODIPY-phenylanthracene dyad for application in photodynamic therapy

Susan Callaghan, Mikhail A. Filatov, Huguette Savoie, Ross W. Boyle, Mathias O. Senge

Research output: Chapter in Book/Report/Conference proceedingConference contributionpeer-review

Abstract

Over the past four years we have developed BODIPY dyads capable of triplet state generation from charge transfer states generated by photoinduced electron transfer. In the current work we identify a lead compound for application in photodynamic therapy. This system is composed of a phenylanthracene electron donor unit and a dimethyl-substituted BODIPY acceptor unit. We have demonstrated that this compound, in sub-micromolar concentrations, can effectively generate singlet oxygen in polar solvents and induce cytotoxicity in human breast cancer cells (MDA-MB-468) when exposed to light. The photophysical properties of these compounds are chemically tunable and thus open the door not only to a new class of photodynamic therapy photosensitizers, but also agents for triplet-triplet annihilation up-conversion applications.

Original languageEnglish
Title of host publication17th International Photodynamic Association World Congress
EditorsTayyaba Hasan
PublisherSPIE
ISBN (Electronic)9781510628335
DOIs
Publication statusPublished - 2019
Event17th International Photodynamic Association World Congress 2019 - Cambridge, United States
Duration: 28 Jun 20194 Jul 2019

Publication series

NameProceedings of SPIE - The International Society for Optical Engineering
Volume11070
ISSN (Print)0277-786X
ISSN (Electronic)1996-756X

Conference

Conference17th International Photodynamic Association World Congress 2019
Country/TerritoryUnited States
CityCambridge
Period28/06/194/07/19

Keywords

  • BODIPY
  • Photodynamic Therapy
  • Photosensitizer
  • Singlet Oxygen
  • Triplet State

Fingerprint

Dive into the research topics of 'A lead BODIPY-phenylanthracene dyad for application in photodynamic therapy'. Together they form a unique fingerprint.

Cite this